GlassScriptPhysician profile
Jiin T Lin
NPI 1306813183
$6,490.78
in general payments reported to CMS, 2019-2025
22 companies · $376 in 2025
The $376 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,327 · 2020: $180 · 2021: $1,172 · 2022: $1,372 · 2023: $1,193 · 2024: $871 · 2025: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,405 · Education: $35.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,404.87 |
| Education | $35.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $984.14 | 2019-2024 | Jardiance |
| Abbvie INC. | $780.62 | 2019-2022 | |
| Gilead Sciences, INC. | $620.69 | 2019-2025 | Vemlidy |
| Glaxosmithkline, LLC. | $619.27 | 2021-2025 | Shingrix, Arexvy, Flulaval Quadrivalent |
| Astrazeneca Pharmaceuticals LP | $571.91 | 2020-2024 | Fasenra, Farxiga, Airsupra |
| Paratek Pharmaceuticals, INC. | $566.91 | 2021-2023 | Nuzyra |
| Lilly USA, LLC | $493.60 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $316.82 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $269.45 | 2019 | |
| Ibsa Pharma INC. | $264.20 | 2022-2024 | Licart |
| Novo Nordisk INC | $233.99 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $156.23 | 2024-2025 | Zoryve |
| Electromed, INC. | $151.70 | 2023-2024 | Smartvest |
| Mallinckrodt Hospital Products INC. | $128.12 | 2021-2022 | |
| Amarin Pharma, INC. | $100.00 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $98.22 | 2024-2025 | |
| Almatica Pharma LLC | $30.07 | 2024 | Loreev Xr |
| Hologic Sales and Service, LLC | $23.89 | 2023 | Aptima |
| Vbi Vaccine (Delaware) INC. | $22.65 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.33 | 2023 | Quviviq |
| Exact Sciences Corporation | $19.22 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $18.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiin Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.